At InterPhex 2026, one challenge stands out: scaling complex biologics affordably. Just-Evotec Biologics is redefining the model with AI-driven design and continuous manufacturing — reshaping access to next-generation therapies.

In this episode of Discovery Matters by Cytiva, innovation is explored from both a scientific and deeply human perspective. Insights are shared on how AI, precision partnering, empathy, and behavioural insight are reshaping life sciences.

Explore how life science companies can benefit from thinking about their end goals from the very beginning. Featuring insights from industry experts, it highlights how early decisions around IP, strategy, and structure can shape long-term outcomes. A concise look at the perspectives shared ahead of The End Game seminar.

The Spring Salon marks the arrival of spring in the Nordics, an evening of connection, renewal, and art for the life science community. Join us on April 28 at Skeppsbron 10 as our space transforms into a gallery featuring Emma Jelk and Jullianne Jabol.

In metastatic colorectal cancer, where treatment options are limited, new approaches are urgently needed. At Charité Berlin, Professor Sebastian Stintzing is advancing a novel combination of immunotherapy and personalized vaccination—aiming to improve outcomes through smarter patient selection and innovative trial design.

Bridging Nordic scientific rigour with American ambition could be key to unlocking larger investments in life sciences. By combining deep expertise with bold capital strategies, investors like Flerie are helping catalyse bigger funding rounds and accelerating innovation from lab to market.

Building a biotech startup mirrors raising a child: a journey fueled by vision, uncertainty, and relentless commitment. From fragile beginnings to eventual independence, both evolve through phases of rapid growth, doubt, and transformation — requiring founders to nurture, adapt, and ultimately learn to let go as their creation takes on a life of its own.

PRESS RELEASE - A group of Nordic life science leaders will travel to the United Kingdom from 7 to 12 June as part of Venture Road UK, an initiative designed to strengthen collaboration between two of Europe’s leading life science ecosystems.

Global partnering in life sciences is entering a new era shaped by geopolitical shifts, financial pressure, and rapid innovation. In her latest column, Helena Strigård highlights how success now depends on global agility, strategic alliances, and the ability to move fast across markets. A must-read for understanding the new rules driving growth and opportunity in today’s biotech landscape.

From a single evening of generosity to life-saving action on the ground, the Impact Day Gala became more than a moment—it became momentum. The funds raised are now translating into critical neurosurgical missions, where expertise meets urgent need.

Featuring Diamyd Medical, the discussion explores a groundbreaking approach to preserving the body’s own insulin production through immune system research. A must-listen to understand how Swedish innovation is gaining momentum on the global stage.

On February 19th, we opened the doors of our new location at Skeppsbron 10, in the heart of Stockholm, marking an exciting milestone for Ventures Accelerated and celebrating the occasion with our community. 

Treos Bio is moving beyond the "trial-and-error" of traditional oncology with a proprietary AI-enabled platform. By using population-scale immunogenomic modelling, the company is shifting the focus to predictable patient outcomes. Watch our interview with CEO Christopher Gallen to learn how the upcoming OBERTO-202 trial aims to validate this data-driven approach in patients with MSS mCRC.

As a new world order takes shape, the European Union faces a defining crossroads. From the "sovereignty trap" of the veto to the revolutionary concept of "European Inc.," this article explores how the EU can move from a house of separate rooms to a single home built on shared power. Read why strategic autonomy is no longer a choice, but a matter of survival.